ClinicalTrials.gg
RecruitingNCT04895436ReVenGUpdated Feb 9, 2026

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

A Phase 2 interventional study of Venetoclax and Obinutuzumab in Chronic Lymphocytic Leukemia (CLL), sponsored by AbbVie. Recruiting at 58 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
34th of 69
75 · median 72
Started
2022
with 4 others
Phase 2
41 of 69
16 open now
Primary completion
2026-11
later than 12 of 41 live
Registered
50th of 69
by date
Lead sponsor
11 of 69
AbbVie

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 34th largest by planned enrollment, is one of 5 that started in 2022, is one of 41 in phase 2, reaches primary completion later than 12 of the 41 other live ones, and was the 50th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed.

Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venetoclax in combination with an anti-CD20 antibody +/- X will be enrolled in the study in approximately 60 sites worldwide.

Participants will receive intravenous (IV) obinutuzumab + oral venetoclax (VenG) in 28-day cycles for a total of 6 cycles per cohort, followed by 6 to 18 cycles of venetoclax alone, for a total treatment of 12 to 24 cycles, depending on the cohort.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Venetoclax
  • ABT-199
  • Venclexta
  • GDC-0199
  • Obinutuzumab
  • Gazyva
  • GA101
  • Cancer
  • ReVenG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of chronic lymphocytic leukemia (CLL) that requires treatment for CLL according to International Workshop for Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria.
  • Previously completed venetoclax + anti-CD20 antibody +/- X regimen as a fixed duration (1L) therapy and achieved documented response, defined as complete remission, complete remission with incomplete marrow recovery, partial remission, or nodular partial remission.
  • More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last dose of venetoclax and disease progression after completion of 1L treatment.

Exclusion criteria

Exclusion Criteria:

- Received intervening treatment for CLL after completing previous treatment with a venetoclax + anti-CD20 antibody +/- X regimen.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - venetoclax + obinutuzumab

    Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles.

    Drug: Venetoclax · Drug: Obinutuzumab

  • Experimental
    Cohort 2 - venetoclax + obinutuzumab

    Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.

    Drug: Venetoclax · Drug: Obinutuzumab

Interventions

  • Oral tablet

    Also known as: Venclexta, ABT-199, GDC-0199

  • Intravenous (IV) infusion

    Also known as: GA101, Gazyva

06

What researchers measure

Primary outcomes

  1. Overall response (OR) in Cohort 1 after end of combination treatment

    OR is defined as the percentage of participants achieving a best response of partial remission (PR), nodular partial remission (nPR), complete remission with incomplete marrow recovery (CRi), or complete remission (CR). Disease assessments will be based on the 2018 International Workshop for Chronic Lymphocytic Leukemia (iwCLL) criteria for tumor response.

    Time frame: 9 months

Secondary outcomes

  1. OR in Cohort 1 after end of combination treatment

    OR rate is defined as the percentage of participants achieving a best response of CR or CRi

    Time frame: 9 months

  2. OR in Cohort 1 after end of treatment

    OR is defined as the percentage of participants achieving a best response of PR, nPR, CRi, or CR. Disease assessments will be based on the 2018 iwCLL criteria for tumor response.

    Time frame: 15 months

  3. Time to Response (TTR) in Cohort 1

    TTR is defined as the time from first dose until first response (PR or better).

    Time frame: 15 months

  4. Duration of Response (DOR) in Cohort 1

    DOR is defined as the time from first response (PR or better) until progressive disease (PD) or death.

    Time frame: 15 months

  5. Time to Next Treatment (TTNT) for CLL in Cohort 1

    TTNT is defined as the time from first dose until first dose of a non-protocol anti-CLL therapy.

    Time frame: 15 months

  6. Progression-free Survival (PFS) in Cohort 1

    PFS is defined as the time from first dose until PD or death.

    Time frame: 15 months

  7. Overall Survival (OS) in Cohort 1

    OS is defined as the time from first dose until death.

    Time frame: 15 months

  8. Percentage of Participants with Undetectable Minimal Residual Disease (uMRD) rate (<10^-4) in Cohort 1 after end of combination treatment

    Percentage of participants with uMRD rate, measured in peripheral blood.

    Time frame: 9 months

  9. Percentage of Participants with Undetectable Minimal Residual Disease (uMRD) rate (<10^-4) in Cohort 1 after end of treatment

    Percentage of participants with uMRD rate, measured in peripheral blood.

    Time frame: 15 months

07

Study locations

50 of 58 sites recruiting
  • Moores Cancer Center at UC San Diego /ID# 230157
    La Jolla, California 92093, United States
    Recruiting
  • Winship Cancer Institute of Emory University /ID# 230643
    Atlanta, Georgia 30322, United States
    Recruiting
  • Des Moines Oncology Research Association /ID# 232606
    Des Moines, Iowa 50309-1423, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dana-Farber Cancer Institute /ID# 230061
    Boston, Massachusetts 02215, United States
    Recruiting
  • Henry Ford Hospital /ID# 230268
    Detroit, Michigan 48202, United States
    Completed

    Not enrolling at this site — choose another above.

  • St. Lukes Hospital of Duluth /ID# 250021
    Duluth, Minnesota 55805, United States
    Recruiting
  • Hattiesburg Clinic /ID# 233443
    Hattiesburg, Mississippi 39401, United States
    Recruiting
  • Summit Medical Group-Florham Park /ID# 244782
    Florham Park, New Jersey 07932-1049, United States
    Completed

    Not enrolling at this site — choose another above.

  • Regional Cancer Care Associates /ID# 244620
    Hackensack, New Jersey 07601-7015, United States
    Recruiting
  • University of North Carolina /ID# 233313
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • Novant Health Presbyterian Medical Center /ID# 230201
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Novant Health Forsyth Medical Center /ID# 249533
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • The Ohio State University /ID# 230439
    Columbus, Ohio 43210, United States
    Recruiting
  • Pennsylvania Oncology Hematolo /ID# 249637
    Philadelphia, Pennsylvania 19106, United States
    Recruiting
  • University of Wisconsin-Madiso /ID# 232612
    Madison, Wisconsin 53705, United States
    Completed

    Not enrolling at this site — choose another above.

  • Royal Adelaide Hospital /ID# 229898
    Adelaide, South Australia 5000, Australia
    Recruiting
  • Northern Hospital Epping /ID# 229847
    Epping, Victoria 3076, Australia
    Recruiting
  • Peter MacCallum Cancer Ctr /ID# 254634
    Melbourne, Victoria 3000, Australia
    Recruiting
  • Universitaetsklinikum St. Poelten /ID# 243493
    Sankt Pölten, Lower Austria 3100, Austria
    Recruiting
  • Medizinische Universitaet Wien /ID# 230013
    Vienna, State of Vienna 1090, Austria
    Recruiting
  • Klinik Ottakring /ID# 230019
    Vienna, State of Vienna 1160, Austria
    Recruiting
  • Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 267569
    Leoben, Styria 8700, Austria
    Recruiting
  • Ordensklinikum Linz GmbH Barmherzige Schwestern /ID# 249516
    Linz, Upper Austria 4010, Austria
    Recruiting
  • Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 230015
    Salzburg, 5020, Austria
    Completed

    Not enrolling at this site — choose another above.

  • Hanusch Krankenhaus /ID# 230010
    Vienna, 1140, Austria
    Recruiting
  • Hospital de Clinicas de Porto Alegre /ID# 243657
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Nove de Julho /ID# 243658
    São Paulo, São Paulo 01409-001, Brazil
    Recruiting
  • Instituto de Ensino e Pesquisas Sao Lucas /ID# 243659
    São Paulo, 01236-030, Brazil
    Recruiting
  • UMHAT Sveti Georgi EAD /ID# 272321
    Plovdiv, 4002, Bulgaria
    Recruiting
  • MHAT Hristo Botev /ID# 229687
    Vratsa, 3000, Bulgaria
    Recruiting
  • Stauferklinikum Schwaebisch Gmuend /ID# 230176
    Mutlangen, Baden-Wurttemberg 73557, Germany
    Recruiting
  • Universitaetsklinikum Ulm /ID# 230164
    Ulm, Baden-Wurttemberg 89081, Germany
    Recruiting
  • VK&K Studien GbR /ID# 230198
    Landshut, Bavaria 84036, Germany
    Recruiting
  • Muenchen Klinik Schwabing /ID# 230197
    Munich, Bavaria 80804, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitaetsmedizin Rostock /ID# 230190
    Rostock, Mecklenburg-Vorpommern 18057, Germany
    Recruiting
  • Universitaetsklinikum Koeln /ID# 230296
    Cologne, North Rhine-Westphalia 50937, Germany
    Recruiting
  • Universitaetsklinikum des Saarlandes /ID# 248747
    Homburg, Saarland 66424, Germany
    Recruiting
  • BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 230168
    Dresden, Saxony 01307, Germany
    Recruiting
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 230186
    Kiel, Schleswig-Holstein 24105, Germany
    Recruiting
  • Onkologische Schwerpunktpraxis /ID# 245465
    Berlin, 10707, Germany
    Recruiting
  • Charite Universitaetsmedizin Berlin Campus Virchow-Klinikum /ID# 248748
    Berlin, 13353, Germany
    Recruiting
  • Duplicate_DIAKO Ev. Diakonie-Krankenhaus gemeinnuetzige GmbH /ID# 230238
    Bremen, 28239, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Essen /ID# 230181
    Essen, 45147, Germany
    Recruiting
  • Universitaetsklinikum Halle (Saale) /ID# 245350
    Halle, 06120, Germany
    Recruiting
  • OncoResearch Lerchenfeld GmbH /ID# 230191
    Hamburg, 22081, Germany
    Recruiting
  • Klinikum Landshut AdöR der Stadt Landshut /ID# 242991
    Landshut, 84034, Germany
    Recruiting
  • Bruederkrankenhaus St. Josef Paderborn /ID# 230177
    Paderborn, 33098, Germany
    Recruiting
  • Hadassah /ID# 245059
    Jerusalem, Jerusalem 91120, Israel
    Recruiting
  • The Chaim Sheba Medical Center /ID# 243219
    Ramat Gan, Tel Aviv 5265601, Israel
    Recruiting
  • Tel Aviv Sourasky Medical Center /ID# 243218
    Tel Aviv, Tel Aviv 6423906, Israel
    Recruiting
  • Rabin Medical Center. /ID# 243220
    Petah Tikva, 4941492, Israel
    Recruiting
  • A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 229504
    Turin, Piedmont 10126, Italy
    Recruiting
  • Azienda Ospedaliera Santa Maria Terni /ID# 229442
    Terni, 05100, Italy
    Recruiting
  • Fundeni Clinical Institute /ID# 241614
    Bucharest, Bucharest 022328, Romania
    Recruiting
  • Hospital Universitario de la Princesa /ID# 229665
    Madrid, 28006, Spain
    Recruiting
  • Blackpool Victoria Hospital /ID# 267280
    Blackpool, Lancashire FY3 8NR, United Kingdom
    Recruiting
  • Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 250733
    Norwich, Norfolk NR4 7UY, United Kingdom
    Recruiting
  • Leeds Teaching Hospitals NHS Trust /ID# 250732
    Leeds, West Yorkshire LS9 7TF, United Kingdom
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Nov 2026, 56 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's planned 56 months is close to that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2021
First posted
May 20, 2021
StartActual
Mar 28, 2022
Primary completionEst.
Nov 2026
CompletionEst.
Jan 2029
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04895436
Lead sponsor
AbbVie
Collaborators
F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute
Responsible party
Sponsor
First posted
May 20, 2021
Start date
Mar 28, 2022
Primary completion
Nov 2026 (estimated)
Completion
Jan 2029 (estimated)
Last update
Feb 9, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Obinutuzumab

Start the discussion